With over €47,000 on the counter, Kiemeney can see the Tour de France as a great success. Not only did he get close to his target amount (you can still donate!), but Bart was also one of the few to have covered the entire course of this edition of the Tour de France.
"Now I'm really not going to cycle the Tour anymore!” the professor writes in his epilogue.
Bart's Tour de France
Read the entire epilogue on www.tourdefrancevanbart.nl or donate.That's still possible!
-
Want to know more about these subjects? Click on the buttons below for more news.
RIHSHealth EvidenceHealthcare improvement scienceUrology Rare cancersTumors of the digestive tract Urological cancersWomen's cancers
Related news items
Large AI project receives over €95 million for ten years of public-private research
23 September 2021Radboud university medical center (Radboudumc) participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboud university medical center leads five of these eight labs.
read more
Reading ADP-ribosylation signaling using chemical biology and interaction proteomics published in Molecular Cell
22 September 2021Kasia Kliza and Michiel Vermeulen worked on a project to synthesize biotinylated ADPr-based probes that can identify ADPr readers and determine their specificity for mono- and polyADPr. They published this in Molecular Cell.
read more
Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield
22 September 2021Christian Gilissen and colleagues published in Genetics in Medicine about their work guiding the application of short tandem repeat analysis in clinical exome sequencing.
read more
TropIQ seeks new mosquito repellents
21 September 2021TropIQ Health Sciences, a Radboudumc spin-off, has received a 1.3 million USD grant from the Bill & Melinda Gates Foundation to track down new mosquito repellents.
read more
New start-up Patholyt will bring AI research into pathology diagnostics
21 September 2021Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.
read more
Treatment of most common skin cancer can sometimes wait
20 September 2021Not treating but keeping an eye on the cancer is also an option
read more